Trial · NCT05575973
Mitoxantrone Hydrochloride Liposome Combined With Rituximab and Lenalidomide (M+R2) in Patients With Relapsed and Refractory Diffuse Large B-Cell Lymphoma
NCT05575973, Phase 2, Unknown, Jianfeng Zhou
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Mitoxantrone Hydrochloride Liposome Combined With Rituximab and Lenalidomide (M+R2) in Patients With Relapsed and Refractory Diffuse Large B-Cell Lymphoma. Trials, record NCT05575973. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT05575973
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Mitoxantrone Hydrochloride Liposome Combined With Rituximab and Lenalidomide (M+R2) in Patients With Relapsed and Refractory Diffuse Large B-Cell Lymphoma
- NCT number
- NCT05575973
- Status
- Unknown
- Phases
- Phase 2
- Enrollment
- 55 participants, estimated
- Lead sponsor
- Jianfeng Zhou
- Conditions
- Diffuse Large B-cell Lymphoma
- Interventions
- Mitoxantrone Hydrochloride Liposome, Rituximab, Lenalidomide
- First posted
- 2022-10-12
- Last updated
- 2022-10-12
Source ClinicalTrials.gov
Registered outcomes8
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Objective response rate (ORR) | through study completion, an average of 2 year | To investigate the preliminary antitumor efficacy |
| Secondary | Progression free survival (PFS) | through study completion, an average of 2 year | To investigate the preliminary antitumor efficacy |
| Secondary | Duration of relief (DOR) | through study completion, an average of 2 year | To investigate the preliminary antitumor efficacy |
| Secondary | Disease Control Rate (DCR) | through study completion, an average of 2 year | To investigate the preliminary antitumor efficacy |
| Secondary | Best of response (BOR) | 6-8 weeks | To investigate the preliminary antitumor efficacy |
| Secondary | Safety endpoint: The incidence and severity of AE and SAE Safety endpoint: The incidence and severity of AE and SAE Safety endpoint:The incidence and severity of AE and SAE | through study completion, an average of 2 year | To identify the incidence and severity of AE and SAE (NCI CTCAE v5.0) |
| Other | Efficacy assessed by IgNGS | through study completion, an average of 2 year | Efficacy assessed by IgNGS |
| Other | Other metrics that researchers are interested | through study completion, an average of 2 year | Other metrics that researchers are interested |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT05575973
GET https://conductscience.org/api/trials/v1/NCT05575973/registered